Monty K. Allen
Known title: DirectorCIK: 0001253352
Associated companies
Transaction History
| IRMD | ▼ Sell | Open Market | 1,014 | $88K | 9/3/2026 | View on chart |
| IRMD | ▼ Sell | Open Market | 405 | $35K | 9/3/2026 | View on chart |
| IRMD | ▼ Sell | Open Market | 1,000 | $100K | 2/13/2026 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 905 | — | 12/11/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,197 | — | 12/7/2025 | View on chart |
| IRMD | ▼ Sell | Open Market | 1,102 | $76K | 8/6/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,751 | — | 12/7/2024 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,196 | — | 12/7/2024 | View on chart |
| IRMD | ▼ Sell | Open Market | 1,947 | $84K | 6/3/2024 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,036 | — | 12/7/2023 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,750 | — | 12/7/2023 | View on chart |
| IRMD | ▼ Sell | Open Market | 2,786 | $128K | 5/10/2023 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 2,037 | — | 12/7/2022 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,035 | — | 12/7/2022 | View on chart |
| IRMD | ▼ Sell | Open Market | 3,072 | $116K | 8/4/2022 | View on chart |
| IRMD | ▼ Sell | Open Market | 1,000 | $47K | 2/24/2022 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 2,185 | — | 12/7/2021 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 2,037 | — | 12/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
iRadimed Gets Needham Hold Rating and Conference Participation
Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.
iRadimed Gets Needham Hold Rating and Conference Participation. Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.